查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1750857

人类乳突病毒 (HPV) 疫苗市场规模、份额、趋势分析报告：按类型、疾病、分销管道、地区、细分市场预测，2025-2030 年

Human Papillomavirus Vaccines Market Size, Share & Trends Analysis Report By Type (Bivalent, Quadrivalent, Nonavalent), By Disease (Cervical Cancer, Anal Cancer), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 195 Pages | 商品交期: 2-10个工作天内

价格

人类乳突病毒疫苗市场的成长与趋势

根据Grand View Research, Inc.的最新报告，预计到2030年全球人类乳突病毒疫苗市场规模将达到140.3亿美元，2025-2030年期间的复合年增长率为8.82%。

各国政府和国际卫生组织越来越多地参与推广人类乳突病毒(HPV)疫苗，这大大推动了市场成长。例如，2024 年 11 月，寮国人民民主共和国 (Lao-PDR)卫生署与联合国儿童基金会、世界卫生组织 (WHO)、全球疫苗免疫联盟 (Gavi) 合作，并在澳洲政府的支持下，正式启动了 2024 年人类乳突病毒 (HPV) 疫苗宣传活动。在全球疫苗免疫联盟、世卫组织和泛美卫生组织等全球组织的资金支持下，许多国家已将人类乳突病毒(HPV)疫苗纳入国家免疫计画。这类合作正在扩大中低收入国家获得疫苗的机会，帮助这些国家克服成本障碍和后勤挑战。

此外，学校疫苗接种计画在涵盖青少年方面特别有效，青少年是HPV预防的主要目标族群。泛美卫生组织的循环基金和世界卫生组织对Cervavac和Walrinvax等新疫苗的核准程序也正在扩大可及的疫苗接种范围。随着越来越多的国家努力实现世界卫生组织消除子宫颈癌的目标， 人类乳突病毒(HPV)疫苗疫苗接种正成为国家战略的支柱，推动公共和私营部门的需求，并创造巨大的市场机会。

提高全球对 HPV 感染、相关健康风险和疫苗接种益处的认识是推动市场成长的主要因素。公共卫生宣传活动、社群媒体推广和学校教育计画在改变观念和鼓励疫苗接种方面发挥关键作用。在拥有强大医疗传播策略的国家，如澳洲和英国， 人类乳突病毒(HPV)疫苗接种率明显较高，这反映了持续的基于证据的提高认识工作的有效性。性别中立的疫苗讯息也提高了男性族群的接受度，特别是考虑到男性口咽癌和肛门癌的发生率不断上升。随着性健康耻辱感的消退和越来越多的人意识到疫苗接种的长期预防癌症益处，越来越多的人开始接种疫苗。这些提高意识的努力不仅增加了需求，而且还带来了更早的疫苗接种、更高的遵从率和更稳定的市场成长。

全球 HPV 相关癌症（尤其是子宫颈癌）的盛行率不断上升，是人类乳突病毒(HPV)疫苗市场强劲的成长动力之一。根据世界卫生组织 (WHO) 预测，2022 年子宫颈癌将成为女性第四大常见癌症，全球将导致超过 342,000 人死亡。约 95% 的子宫颈癌病例与持续感染高危险 HPV 类型有关，主要是 16 型和 18 型。同样，其他 HPV 相关癌症（包括口咽癌、肛门癌、阴茎癌、阴道癌和外阴癌）的发生率也在上升，尤其是在高所得国家。例如，在美国，目前超过 70% 的口咽癌与 HPV 有关，而且这种趋势在过去十年中稳步上升。日益加重的疾病负担提升了人类乳突病毒(HPV)疫苗作为公共卫生挑战的作用。随着诊断和监测技术的进步以及 HPV 相关癌症数据变得更加丰富，迫切需要实施广泛的疫苗接种策略，尤其是在青少年中，从而加速全球市场的需求。

人类乳突病毒疫苗市场报告重点

  • 按类型划分，四价疫苗预计将在2024年占据75.67%的市场占有率，因为它们对四种主要HPV类型——6、11、16和18——具有全面的保护作用。已知这四种类型的HPV导致近70%的子宫颈癌病例和近90%的生殖器湿疣，这使得四价疫苗成为全球HPV疫苗接种策略的关键组成部分。
  • 按疾病划分，子宫颈癌占据市场主导地位，2024 年的收入份额为 63.78%。子宫颈癌是最常见的 HPV 相关恶性肿瘤之一，主要由 HPV 16 型和 18 型引起，约占所有病例的 70%。
  • 从分销通路来看，医院和零售药局预计将在2024年占据最大份额，达到54.75%，并在预测期内以最快的速度成长。这一趋势主要源自于这些医疗机构为寻求人类乳突病毒(HPV)疫苗的患者提供的日益便捷、可靠和便捷的接种体验。
  • 到 2024 年，北美将以 39.83% 的份额引领全球市场，这得益于广泛的疫苗接种覆盖率、强有力的公共卫生宣传活动以及公共和私人医疗保健系统早期采用人类乳突病毒(HPV)疫苗，从而确保广泛的人口保护。
  • 全球人类乳突病毒(HPV)疫苗市场的主要参与者包括默克公司、葛兰素史克公司 (GSK) 和印度血清研究所私人有限公司。所有主要企业都在透过推出新产品、建立策略伙伴关係关係和扩展到新地区等策略来加强其在全球的地位。

目录

第一章调查方法与范围

第二章执行摘要

3. 人类乳突病毒（HPV）疫苗市场变数、趋势和范围

  • 市场区隔和范围
  • 市场体系展望
    • 母市场展望
    • 相关/支持市场展望
  • 市场趋势与展望
  • 市场动态
    • HPV相关癌症发生率不断上升
    • 政府和非政府组织的疫苗接种计划
    • 意识提升和教育活动
    • 医疗成本不断上涨
    • 疫苗技术的进步
  • 市场限制因素分析
    • 疫苗成本高昂
    • 服务欠缺地区的认知度较低
    • 波特五力分析
    • PESTEL分析

4. 人类乳突病毒（HPV）疫苗市场类型、估值及趋势分析

  • 人类乳突病毒（HPV）疫苗市场：类型变异分析
  • 按类型
  • 二价
  • 四价
  • 9价

第五章 人类乳突病毒 (HPV) 疫苗市场：按疾病、估计和趋势分析

  • 人类乳突病毒（HPV）疫苗市场：疾病趋势分析
  • 按疾病
  • 子宫颈癌
  • 阴道癌及外阴癌
  • 肛门癌
  • 口咽癌（头颈癌）
  • 生殖器疣

6. 人类乳突病毒（HPV）疫苗市场通路预测及趋势分析

  • 人类乳突病毒（HPV）疫苗市场：分销管道波动分析
  • 按分销管道
  • 医院和药房
  • 政府供应商
  • 其他的

7. 人类乳突病毒 (HPV) 疫苗市场：区域、估计和趋势分析

  • 2024 年和 2030 年人类乳突病毒 (HPV) 疫苗市场占有率
  • 2024 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 全球区域市场概况
  • 2018-2030年市场规模、预测趋势分析
  • 北美洲
    • 2018-2030年北美人类乳突病毒（HPV）疫苗市场
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 2018-2030年欧洲人类乳突病毒（HPV）疫苗市场
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 2018-2030年亚太地区人类乳突病毒（HPV）疫苗市场
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 泰国
    • 韩国
  • 南美洲
    • 2018-2030年南美人类乳突病毒（HPV）疫苗市场
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 2018-2030年中东和非洲人乳头瘤病毒（HPV）疫苗市场
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争态势

  • 主要市场参与企业的近期趋势和影响分析
  • 公司分类
  • 战略地图
  • 2024年公司市场占有率分析
  • 公司简介
    • Merck &Co., Inc.
    • GlaxoSmithKline plc（GSK）
    • Serum Institute of India Pvt. Ltd.
    • Sanofi Pasteur SA
    • Pfizer Inc.
    • Inovio Pharmaceuticals Inc.
    • Walvax Biotechnology Co., Ltd.
    • Bharat Biotech International Ltd.
    • Johnson &Johnson Services, Inc.
    • Moderna, Inc.
    • Gilead Sciences, Inc.
Product Code: GVR-4-68040-578-3

Human Papillomavirus Vaccines Market Growth & Trends:

The global Human Papillomavirus vaccines market size is expected to reach USD 14.03 billion by 2030, registering a CAGR of 8.82% from 2025 to 2030, according to a new report by Grand View Research, Inc., driven by several key factors. The increasing involvement of governments and international health organizations in promoting HPV vaccination is significantly propelling market growth. For instance, in November 2024, the Ministry of Health of the Lao People's Democratic Republic (Lao PDR), in collaboration with UNICEF, the World Health Organization (WHO), and Gavi, the Vaccine Alliance-with support from the Government of Australia-officially launched the 2024 Human Papillomavirus (HPV) immunization campaign. Many countries have introduced HPV vaccines into their national immunization schedules, often with funding support from global organizations such as GAVI, WHO, and PAHO. These collaborations have expanded access to vaccines in low- and middle-income countries, helping overcome cost barriers and logistical challenges.

In addition, school-based vaccination programs have been particularly effective in reaching adolescent populations, which are the primary target for HPV prevention. The Pan American Health Organization's revolving fund and WHO's prequalification process for new vaccines like Cervavac and Walrinvax have also broadened the landscape of accessible options. As countries increasingly aim to meet the WHO's goal of eliminating cervical cancer, HPV vaccination is becoming a central pillar in their national strategies, boosting both public and private sector demand and creating significant market opportunities.

Increased global awareness regarding HPV transmission, associated health risks, and the benefits of vaccination is a major factor driving market growth. Public health campaigns, social media outreach, and school-based education initiatives have played a pivotal role in changing perceptions and encouraging vaccine acceptance. In countries with robust healthcare communication strategies, such as Australia and the UK, HPV vaccine uptake is notably high, reflecting the impact of consistent, evidence-based awareness efforts. Gender-neutral vaccination messaging has also improved acceptance among male populations, particularly in response to the growing incidence of oropharyngeal and anal cancers in men. As stigma around sexual health diminishes and more people recognize the long-term cancer prevention benefits of vaccination, broader demographic groups are being reached. These awareness initiatives are not only increasing demand but are also leading to earlier vaccination, higher compliance rates, and more consistent market growth.

The increasing global prevalence of HPV-related cancers, particularly cervical cancer, is one of the strongest growth drivers of the HPV vaccines market. According to the World Health Organization (WHO), in 2022, cervical cancer was responsible for over 342,000 deaths worldwide, making it the fourth most common cancer among women. Approximately 95% of cervical cancer cases are linked to persistent infection with high-risk HPV types, primarily types 16 and 18. Similarly, the incidence of other HPV-associated cancers-such as oropharyngeal, anal, penile, vaginal, and vulvar cancers-is on the rise, especially in high-income countries. For example, HPV is now responsible for over 70% of oropharyngeal cancers in the United States, a trend that has been steadily increasing over the past decade. This growing disease burden has elevated the role of HPV vaccination in public health agendas. With improved diagnostics and surveillance, and as HPV-related cancer data becomes more robust, the urgency to implement broad vaccination strategies, particularly for adolescents, is accelerating global market demand.

Human Papillomavirus Vaccines Market Report Highlights:

  • In 2024, the quadrivalent segment held the largest market share of 75.67%, attributed to its comprehensive protection against four major HPV types-6, 11, 16, and 18. These strains are known to cause nearly 70% of cervical cancer cases and about 90% of genital warts, making the quadrivalent vaccine a key component in HPV immunization strategies worldwide.
  • In 2024, the cervical cancer segment dominated the market, capturing a revenue share of 63.78%, driven by increased awareness and strong preventive measures. Cervical cancer is among the most prevalent HPV-related malignancies, primarily caused by HPV types 16 and 18, which are responsible for approximately 70% of all cases.
  • In 2024, the hospitals and retail pharmacies segment held the largest revenue share of 54.75% and is projected to experience the fastest growth during the forecast period. This trend is primarily driven by the growing accessibility, convenience, and reliability that these healthcare facilities offer to patients seeking HPV vaccination.
  • In 2024, North America led the global market with a share of 39.83%, fueled by extensive immunization coverage, robust public health campaigns, and early adoption of HPV vaccines across both public and private healthcare systems, ensuring broad population protection.
  • The global HPV vaccines market is led by several major companies, including Merck & Co., Inc., GlaxoSmithKline plc (GSK), Serum Institute of India Pvt. Ltd., among others. All key companies are strengthening their worldwide presence through strategies like launching new products, forging strategic partnerships, and expanding into new geographic regions.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Disease
    • 1.2.3. Distribution Channel
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline.
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Type outlook
    • 2.2.2. Disease outlook
    • 2.2.3. Distribution channel outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Human Papillomavirus (HPV) Vaccines Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Trends and Outlook
  • 3.4. Market Dynamics
    • 3.4.1. Rising prevalence of HPV-related cancers
    • 3.4.2. Government and NGO immunization programs
    • 3.4.3. Growing Awareness and education initiatives
    • 3.4.4. Increase in healthcare expenditure
    • 3.4.5. Advancements in vaccine technology
  • 3.5. Market Restraint Analysis
    • 3.5.1. High vaccine costs
    • 3.5.2. Limited Awareness in Underserved Regions
    • 3.5.3. Porter's Five Forces Analysis
    • 3.5.4. PESTEL Analysis

Chapter 4. Human Papillomavirus (HPV) Vaccines Market: Type Estimates & Trend Analysis

  • 4.1. Human Papillomavirus (HPV) Vaccines Market: Type Movement Analysis
  • 4.2. Human Papillomavirus (HPV) Vaccines Market Estimates and Forecast, by Type
  • 4.3. Bivalent
    • 4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4. Quadrivalent
    • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Nonavalent
    • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Human Papillomavirus (HPV) Vaccines Market: Disease Estimates & Trend Analysis

  • 5.1. Human Papillomavirus (HPV) Vaccines Market: Disease Movement Analysis
  • 5.2. Human Papillomavirus (HPV) Vaccines Market Estimates and Forecast, by Disease
  • 5.3. Cervical Cancer
    • 5.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4. Vaginal and Vulvar Cancers
    • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Anal Cancer
    • 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Oropharyngeal (Head and Neck) Cancers
    • 5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7. Genital Warts
    • 5.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Human Papillomavirus (HPV) Vaccines Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Human Papillomavirus (HPV) Vaccines Market: Distribution Movement Analysis
  • 6.2. Human Papillomavirus (HPV) Vaccines Market Estimates and Forecast, by Distribution Channel
  • 6.3. Hospitals and Retail Pharmacies
    • 6.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4. Government Suppliers
    • 6.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Others
    • 6.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Human Papillomavirus (HPV) Vaccines Market: Regional Estimates & Trend Analysis

  • 7.1. Human Papillomavirus (HPV) Vaccines Market Share By Region, 2024 & 2030
  • 7.2. Regional Market Share Analysis, 2024 & 2030
  • 7.3. Regional Market Dashboard
  • 7.4. Global Regional Market Snapshot
  • 7.5. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.6. North America
    • 7.6.1. North America Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
    • 7.6.2. U.S.
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Competitive Scenario
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. U.S. Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
    • 7.6.3. Canada
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Competitive Scenario
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Canada Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
    • 7.6.4. Mexico
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Competitive Scenario
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Mexico Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • 7.7. Europe
    • 7.7.1. Europe Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
    • 7.7.2. UK
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Competitive Scenario
      • 7.7.2.3. Regulatory Framework
      • 7.7.2.4. UK Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
    • 7.7.3. Germany
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Competitive Scenario
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. Germany Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
    • 7.7.4. France
      • 7.7.4.1. Key Country Dynamics
      • 7.7.4.2. Competitive Scenario
      • 7.7.4.3. Regulatory Framework
      • 7.7.4.4. France Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
    • 7.7.5. Italy
      • 7.7.5.1. Key Country Dynamics
      • 7.7.5.2. Competitive Scenario
      • 7.7.5.3. Regulatory Framework
      • 7.7.5.4. Italy Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
    • 7.7.6. Spain
      • 7.7.6.1. Key Country Dynamics
      • 7.7.6.2. Competitive Scenario
      • 7.7.6.3. Regulatory Framework
      • 7.7.6.4. Spain Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
    • 7.7.7. Denmark
      • 7.7.7.1. Key Country Dynamics
      • 7.7.7.2. Competitive Scenario
      • 7.7.7.3. Regulatory Framework
      • 7.7.7.4. Denmark Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
    • 7.7.8. Sweden
      • 7.7.8.1. Key Country Dynamics
      • 7.7.8.2. Competitive Scenario
      • 7.7.8.3. Regulatory Framework
      • 7.7.8.4. Sweden Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
    • 7.7.9. Norway
      • 7.7.9.1. Key Country Dynamics
      • 7.7.9.2. Competitive Scenario
      • 7.7.9.3. Regulatory Framework
      • 7.7.9.4. Norway Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • 7.8. Asia Pacific
    • 7.8.1. Asia Pacific Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
    • 7.8.2. Japan
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Competitive Scenario
      • 7.8.2.3. Regulatory Framework
      • 7.8.2.4. Japan Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
    • 7.8.3. China
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Competitive Scenario
      • 7.8.3.3. Regulatory Framework
      • 7.8.3.4. China Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
    • 7.8.4. India
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Competitive Scenario
      • 7.8.4.3. Regulatory Framework
      • 7.8.4.4. India Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
    • 7.8.5. Australia
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Competitive Scenario
      • 7.8.5.3. Regulatory Framework
      • 7.8.5.4. Australia Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
    • 7.8.6. Thailand
      • 7.8.6.1. Key Country Dynamics
      • 7.8.6.2. Competitive Scenario
      • 7.8.6.3. Regulatory Framework
      • 7.8.6.4. Thailand Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
    • 7.8.7. South Korea
      • 7.8.7.1. Key Country Dynamics
      • 7.8.7.2. Competitive Scenario
      • 7.8.7.3. Regulatory Framework
      • 7.8.7.4. South Korea Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • 7.9. Latin America
    • 7.9.1. Latin America Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
    • 7.9.2. Brazil
      • 7.9.2.1. Key Country Dynamics
      • 7.9.2.2. Competitive Scenario
      • 7.9.2.3. Regulatory Framework
      • 7.9.2.4. Brazil Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
    • 7.9.3. Argentina
      • 7.9.3.1. Key Country Dynamics
      • 7.9.3.2. Competitive Scenario
      • 7.9.3.3. Regulatory Framework
      • 7.9.3.4. Argentina Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • 7.10. MEA
    • 7.10.1. MEA Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
    • 7.10.2. South Africa
      • 7.10.2.1. Key Country Dynamics
      • 7.10.2.2. Competitive Scenario
      • 7.10.2.3. Regulatory Framework
      • 7.10.2.4. South Africa Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
    • 7.10.3. Saudi Arabia
      • 7.10.3.1. Key Country Dynamics
      • 7.10.3.2. Competitive Scenario
      • 7.10.3.3. Regulatory Framework
      • 7.10.3.4. Saudi Arabia Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
    • 7.10.4. UAE
      • 7.10.4.1. Key Country Dynamics
      • 7.10.4.2. Competitive Scenario
      • 7.10.4.3. Regulatory Framework
      • 7.10.4.4. UAE Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
    • 7.10.5. Kuwait
      • 7.10.5.1. Key Country Dynamics
      • 7.10.5.2. Competitive Scenario
      • 7.10.5.3. Regulatory Framework
      • 7.10.5.4. Kuwait Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Strategy Mapping
  • 8.4. Company Market Share Analysis, 2024
  • 8.5. Company Profiles
    • 8.5.1. Merck & Co., Inc.
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. GlaxoSmithKline plc (GSK)
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Serum Institute of India Pvt. Ltd.
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Sanofi Pasteur SA
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Pfizer Inc.
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Inovio Pharmaceuticals Inc.
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Walvax Biotechnology Co., Ltd.
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Bharat Biotech International Ltd.
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. Johnson & Johnson Services, Inc.
      • 8.5.9.1. Overview
      • 8.5.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. Moderna, Inc.
      • 8.5.10.1. Overview
      • 8.5.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic Initiatives
    • 8.5.11. Gilead Sciences, Inc.
      • 8.5.11.1. Overview
      • 8.5.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.5.11.3. Product Benchmarking
      • 8.5.11.4. Strategic Initiatives

List of Table

  • Table 1 List of abbreviations
  • Table 2 Global Human Papillomavirus (HPV) Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 3 Global Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
  • Table 4 Global Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 5 Global Human Papillomavirus (HPV) Vaccines Market, by Region, 2018 - 2030 (USD Million)
  • Table 6 North America Human Papillomavirus (HPV) Vaccines Market, by Country, 2018 - 2030 (USD Million)
  • Table 7 North America Human Papillomavirus (HPV) Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 8 North America Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
  • Table 9 North America Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 10 U.S. Human Papillomavirus (HPV) Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 11 U.S. Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
  • Table 12 U.S. Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 13 Canada Human Papillomavirus (HPV) Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 14 Canada Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
  • Table 15 Canada Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 16 Mexico Human Papillomavirus (HPV) Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 17 Mexico Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
  • Table 18 Mexico Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 19 Europe Human Papillomavirus (HPV) Vaccines Market, by Country, 2018 - 2030 (USD Million)
  • Table 20 Europe Human Papillomavirus (HPV) Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 21 Europe America Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
  • Table 22 Europe America Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 23 UK Human Papillomavirus (HPV) Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 24 UK Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
  • Table 25 UK Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 26 Germany Human Papillomavirus (HPV) Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 27 Germany Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
  • Table 28 Germany Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 29 France Human Papillomavirus (HPV) Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 30 France Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
  • Table 31 France Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 32 Italy Human Papillomavirus (HPV) Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 33 Italy Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
  • Table 34 Italy Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 35 Spain Human Papillomavirus (HPV) Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 36 Spain Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
  • Table 37 Spain Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 38 Denmark Human Papillomavirus (HPV) Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 39 Denmark Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
  • Table 40 Denmark Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 41 Sweden Human Papillomavirus (HPV) Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 42 Sweden Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
  • Table 43 Sweden Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 44 Norway Human Papillomavirus (HPV) Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 45 Norway Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
  • Table 46 Norway Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 47 Asia Pacific Human Papillomavirus (HPV) Vaccines Market, by Country, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific Human Papillomavirus (HPV) Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
  • Table 50 Asia Pacific Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 51 Japan Human Papillomavirus (HPV) Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 52 Japan Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
  • Table 53 Japan Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 54 China Human Papillomavirus (HPV) Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 55 China Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
  • Table 56 China Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 57 India Human Papillomavirus (HPV) Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 58 India Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
  • Table 59 India Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 60 Australia Human Papillomavirus (HPV) Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 61 Australia Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
  • Table 62 Australia Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 63 Thailand Human Papillomavirus (HPV) Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 64 Thailand Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
  • Table 65 Thailand Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 66 South Korea Human Papillomavirus (HPV) Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 67 South Korea Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
  • Table 68 South Korea Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 69 Latin America Human Papillomavirus (HPV) Vaccines Market, by Country, 2018 - 2030 (USD Million)
  • Table 70 Latin America Human Papillomavirus (HPV) Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 71 Latin America Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
  • Table 72 Latin America Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 73 Brazil Human Papillomavirus (HPV) Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 74 Brazil Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
  • Table 75 Brazil Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 76 Argentina Human Papillomavirus (HPV) Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 77 Argentina Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
  • Table 78 Argentina Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 79 Middle East & Africa Human Papillomavirus (HPV) Vaccines Market, by Country, 2018 - 2030 (USD Million)
  • Table 80 Middle East & Africa Human Papillomavirus (HPV) Vaccines Market, by type, 2018 - 2030 (USD Million)
  • Table 81 Middle East & Africa Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
  • Table 82 Middle East & Africa Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 83 South Africa Human Papillomavirus (HPV) Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 84 South Africa Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
  • Table 85 South Africa Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 86 Saudi Arabia Human Papillomavirus (HPV) Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 87 Saudi Arabia Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
  • Table 88 audi Arabia Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 89 UAE Human Papillomavirus (HPV) Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 90 UAE Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
  • Table 91 UAE Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 92 Kuwait Human Papillomavirus (HPV) Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 93 Kuwait Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
  • Table 94 Kuwait Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value chain-based sizing & forecasting
  • Fig. 6 Market formulation & validation
  • Fig. 7 Human Papillomavirus (HPV) Vaccines Market segmentation
  • Fig. 8 Market snapshot, 2024
  • Fig. 9 Market trends & outlook
  • Fig. 10 Market driver relevance analysis (current & future impact)
  • Fig. 11 Market restraint relevance analysis (current & future impact)
  • Fig. 12 SWOT analysis, by factor (political & legal, economic, and technological)
  • Fig. 13 Porter's five forces analysis
  • Fig. 14 Human papillomavirus (HPV) vaccines market: Type movement analysis
  • Fig. 15 Human papillomavirus (HPV) vaccines market: Type outlook and key takeaways
  • Fig. 16 Bivalent market estimates and forecast, 2018 - 2030
  • Fig. 17 Quadrivalent market estimates and forecast, 2018 - 2030
  • Fig. 18 Nonavalent market estimates and forecast, 2018 - 2030
  • Fig. 19 Human papillomavirus (HPV) vaccines market: Disease movement analysis
  • Fig. 20 Human papillomavirus (HPV) vaccines market: Disease outlook and key takeaways
  • Fig. 21 Cervical Cancer market estimates and forecast, 2018 - 2030
  • Fig. 22 Vaginal and Vulvar Cancers market estimates and forecast, 2018 - 2030
  • Fig. 23 Anal Cancer market estimates and forecast, 2018 - 2030
  • Fig. 24 Oropharyngeal (Head and Neck) Cancers market estimates and forecast, 2018 - 2030
  • Fig. 25 Genital Warts market estimates and forecast, 2018 - 2030
  • Fig. 26 Human papillomavirus (HPV) vaccines market: Distribution channel movement analysis
  • Fig. 27 Human papillomavirus (HPV) vaccines market: Distribution channel outlook and key takeaways
  • Fig. 28 Hospitals and Retail Pharmacies market estimates and forecast, 2018 - 2030
  • Fig. 29 Government Suppliers market estimates and forecast, 2018 - 2030
  • Fig. 30 Others market estimates and forecast, 2018 - 2030
  • Fig. 31 Regional outlook, 2024 & 2030
  • Fig. 32 Global Human Papillomavirus (HPV) Vaccines Market: Region movement analysis
  • Fig. 33 North America Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 34 U.S. Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 35 Canada Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 36 Mexico Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 37 Europe Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 38 Germany Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 39 UK Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 40 France Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 41 Italy Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 42 Spain Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 43 Denmark Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 44 Sweden Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 45 Norway Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 46 Asia Pacific Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 47 Japan Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 48 China Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 49 India Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 50 Australia Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 51 South Korea Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 52 Thailand Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 53 Latin America Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 54 Brazil Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 55 Argentina Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 56 Middle East and Africa Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 57 South Africa Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 58 Saudi Arabia Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 59 UAE Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 60 Kuwait Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)